Skip to main content

Table 2 Relative risks of death from disease and overall death within 5 years according to clinicopathological factors and ezrin expression in two independent patient cohorts

From: Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts

  Cohort I Cohort II
  Risk of death within 5 years   Risk of death from disease   Risk of death within 5 years
   Unadjusted Adjusted   Unadjusted Adjusted   Unadjusted Adjusted
  n (events) HR (95% CI) HR (95% CI) n (events) HR (95% CI) HR (95% CI) n (events) HR (95% CI) HR (95% CI)
Age          
Continuous 100(46) 1.05(1.02-1.08) 1.05(1.02-1.08) 300(100) 1.05(1.03-1.07) 1.05(1.02-1.07) 342(170) 1.06(1.05-1.08) 1.07(1.05-1.08)
Gender          
Female 25(11) 1.00 1.00 71(28) 1.00 1.00 82(40) 1.00 1.00
Male 75(35) 0.96(0.49-1.89) 1.12(0.54-2.31) 227(72) 0.79(0.51-1.22) 1.03(0.66-1.61) 260(130) 0.97(0.68-1.38) 1.20(0.83-1.72)
Stage          
Ta 41(7) 1.00 1.00 104(13) 1.00 1.00 115(35) 1,00 1.00
T1 22(15) 5.06(2.06-12.46) 2.20(0.73-6.68) 97(25) 2.20(1.13-4.31) 2.17(1.11-4.25) 116(53) 1.63(1.06-2.50) 1.57(1.02-2.40)
T2-4 37(24) 6.15(2.64-14.31) 2.44(0.73-8.19) 97(62) 8.86(4.86-16.16) 8.70(4.76-15.89) 111(82) 4.34(2.91-6.46) 4.36(2.92-6.52)
Grade          
Low 44(9) 1.00 1.00 75(7) 1.00 1.00 82(20) 1.00 1.00
High 56(37) 4.71(2.27-9.79) 2.94(1.32-6.53) 223(93) 5.75(2.66-12.39) 1.67(0.64-4.35) 260(150) 3.09(1.94-4.93) 1.20(0.67-2.13)
Ezrin expression*         
High 59(19) 1.00 1.00 136(27) 1.00 1.00 120(40) 1.00 1.00
Low 41(27) 3.09(1.71-5.58) 1.99(1.05-3.77) 162(73) 2.77(1.78-4.31) 1.23(0.75-2.02) 222(130) 2.15(1.51-3.06) 1.24(0.84-1.84)
  1. *High and low expression determined by CRT-analysis; cutoff 17.5% for 5-year OS in Cohort I, 27.5% for for 5-year OS in Cohort II and 12.5% for DSS in cohort II.